When to Resume Apixaban (Eliquis) After Variceal Band Ligation
Resume apixaban 7 days after variceal band ligation in patients at low thrombotic risk, or within 3 days with heparin bridging in patients at high thrombotic risk, once adequate hemostasis has been established.
Risk-Based Approach to Resumption
The timing of anticoagulation resumption after variceal banding must balance two competing risks: post-banding ulcer bleeding (which peaks at 10-14 days and carries 25-50% mortality) versus thromboembolic events from prolonged anticoagulation interruption.
Procedural Context
Variceal band ligation is classified as a high-risk bleeding procedure 1. The FDA label for apixaban states it should be discontinued at least 48 hours prior to procedures with moderate or high bleeding risk, and restarted "as soon as adequate hemostasis has been established" 2. However, this generic guidance requires clinical interpretation in the context of variceal banding.
Thrombotic Risk Stratification
Low Thrombotic Risk Patients:
- Atrial fibrillation without recent stroke/TIA
- Remote VTE (>3 months ago)
- Peripheral vascular disease
For these patients: Resume apixaban at 7 days post-procedure 1
High Thrombotic Risk Patients:
- Recent VTE (<3 months)
- Mechanical heart valves
- Recent stroke/TIA
- Active cancer with VTE
For these patients: Resume anticoagulation within 3 days using heparin bridging, then transition to apixaban 1
Key Clinical Considerations
Post-Banding Ulcer Bleeding Risk
Post-banding ulcers typically bleed between days 10-14 after the procedure 3. This creates a critical window where resuming anticoagulation too early (days 1-6) substantially increases bleeding risk during the peak ulcer formation period. The 7-day recommendation for low-risk patients strategically positions resumption just before the peak bleeding window while minimizing thrombotic exposure.
Cirrhosis-Specific Factors
Important caveat: Patients with cirrhosis should follow the same anticoagulation management guidelines as non-cirrhotic patients 3. Despite theoretical concerns about altered drug metabolism in cirrhosis, studies show that anticoagulant use during variceal banding does not significantly increase post-procedure bleeding risk 3. The risk factors for post-banding bleeding are secondary prophylaxis status and prior decompensation—not anticoagulant use itself.
Hemostasis Verification
Before resuming apixaban at any timepoint, confirm:
- No active bleeding from banding sites
- Stable hemoglobin over 24-48 hours
- No hematemesis or melena
- Hemodynamic stability
Practical Algorithm
Day 0 (Procedure Day): Discontinue apixaban (should have been stopped 48 hours pre-procedure)
Days 1-6: Hold anticoagulation for ALL patients
- Monitor for bleeding
- Assess thrombotic risk category
Day 7 (Low Thrombotic Risk):
- Verify hemostasis established
- Resume apixaban at usual dose
Day 3 (High Thrombotic Risk):
- Start heparin bridging (LMWH or unfractionated heparin)
- Continue until day 7-10
- Transition to apixaban once past peak ulcer bleeding window
Days 10-14: Peak ulcer bleeding risk period
- If bleeding occurs, stop anticoagulation immediately
- Manage bleeding per standard protocols
Common Pitfalls to Avoid
- Don't resume too early: Resuming before day 7 in low-risk patients exposes them to peak ulcer bleeding risk without sufficient thrombotic benefit
- Don't delay indefinitely in high-risk patients: Prolonged interruption beyond 7 days in high-risk patients increases stroke/VTE risk substantially
- Don't forget bridging in high-risk patients: These patients need anticoagulation coverage starting day 3, but use shorter-acting agents (heparin) that can be rapidly reversed if bleeding occurs
- Don't assume cirrhosis changes the algorithm: The same timing applies regardless of liver disease 3
The evidence quality for these specific timeframes is low 1, but the recommendations represent consensus expert opinion balancing the known natural history of post-banding ulcer bleeding against thrombotic risk stratification principles.